LixiLan
Teva and Samsung Bioepis to commercialise two FDA-approved biosimilars in the US
Teva will get US commercialisation rights for Eticovo upon close and infliximab in Q3 2027
Fresenius and WuXi Biologics announce agreement to expand biosimilars pipeline
The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates
Novo Nordisk UK appoints George Godfrey as Senior Director, Medical & Regulatory
Godfrey previously served as Head of Medical for Respiratory and Immunology for AstraZeneca UK
Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses
SPMS is a debilitating stage of MS where patients experience increasing levels of disability
Sanofi appoints Paulo Fontoura as Global Head of R&D
Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche
Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector
It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma
Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes
The treatment can be used to delay the onset of clinical type 1 diabetes
Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes
The insulin is designed as an alternative to daily basal insulin
Sandoz partners with Samsung Bioepis to develop up to five biosimilars
The agreement will expand the pipeline and builds on an existing partnership
Novo Nordisk elects employee representatives to Board of Directors
The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026